Global Drugmakers Expand US Operations Amid Tariff Threats
In response to potential 100% tariffs on branded drugs under the Trump administration, global pharmaceutical companies are increasing their U.S. manufacturing presence and stockpiling inventory. Key firms like Pfizer, AstraZeneca, Eli Lilly, Johnson & Johnson, Merck, and GSK have committed billions in investments or secured tariff exemptions through pricing agreements.
Tickers: $AZN $JNJ $LLY $MRK $PFE